Does Vitamin E Mitigate Cisplatin-induced Nephrotoxicity in Cancer Patients: Results from a Randomized Placebo-Controlled Clinical Trial

Background: cisplatin (cp) is a potent antineoplastic agent in the treatment of wide a range of cancers, but it is accompanied with nephrotoxicity, a major limiting side effect. the aim of the present study was to evaluate the possible protective effect of vitamin e in the prevention of cp-induced nephrotoxicity. method: in this randomized clinical trial, a total of 51 patients treated with cp chemotherapy were randomly assigned to receive vitamin e supplementation (400 iu/ daily) (n=26) or placebo (n=25). serum creatinine, glomerular filtration rate (gfr), and neutrophil gelatinase-associated lipocalin were measured prior to each chemotherapy cycle and one month after the cessation of the cycles. result: compared to the baseline, a significant decrease was observed in the blood levels of neutrophil gelatinase-associated lipocalin and serum creatinine in the vitamin e group (p=0.001). gfr was not reduced in the vitamin e group (p=0.001), and vitamin e was generally tolerated well. conclusion: our findings indicated that vitamin e exert protective effects against cp-induced nephrotoxicity, a finding which requires larger studies for confirmation.